FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms

FDA Approves Orzeyful for Full Range of Narcolepsy Type 1 Symptoms

The U.S. Food and Drug Administration (FDA) has approved Orzeyful (oveporexton) tablets for the treatment of narcolepsy type 1 in adults. This marks the first medicine approved to address the full range of symptoms of narcolepsy type 1 and the first to directly restore orexin signaling, targeting the underlying biological cause of the disease. The approval is based on two randomized, double-blind, placebo-controlled 12-week studies involving 273 adults, which demonstrated improvements in wakefulness, reduced daytime sleepiness, and significant reductions in cataplexy, sleep paralysis, hallucinations, and disrupted nighttime sleep.

• Orzeyful represents a significant advancement as the first medicine to directly activate the brain receptor that the body's own orexin would normally stimulate, thereby restoring the missing signal. This novel mechanism of action targets the fundamental biological cause of narcolepsy type 1, moving beyond symptomatic management with stimulants or sedatives.
• Clinical trials demonstrated comprehensive efficacy, with Orzeyful 2 mg showing improvements in the ability to stay awake during the day and substantially less daytime sleepiness compared to placebo. Patients also experienced significant reductions in cataplexy episodes and meaningful improvements across the full spectrum of narcolepsy symptoms, including sleep paralysis, hallucinations, and disrupted nighttime sleep.
• The drug received Breakthrough Therapy Designation and Priority Review, underscoring its potential to offer substantial improvements for a serious condition. Common side effects included insomnia, increased urinary frequency, urgency to urinate, and increased saliva production, with a low rate of treatment discontinuation. Orzeyful should not be used concurrently with strong CYP3A inhibitors.

Why Current Narcolepsy Type 1 Treatments Fall Short

Despite the availability of pharmacological agents, current treatment strategies for narcolepsy type 1 (NT1) are often insufficient, addressing symptoms rather than the underlying pathophysiology. This symptomatic approach results in significant residual disease burden, impacting patient adherence, daily functioning, and overall quality of life. The limitations of the current treatment paradigm create a high unmet need for more comprehensive and effective therapeutic options.

• Incomplete Symptom Control: Current pharmacological treatments rarely achieve complete and sustained symptom control. Many patients continue to experience significant residual impairment, particularly persistent excessive daytime sleepiness (EDS). This is largely because available therapies are symptomatic—improving EDS and/or reducing cataplexy—but do not correct the core hypocretin/orexin deficiency that defines NT1.

• Significant Barriers to Treatment Adherence: Adherence to medication is a major challenge, with studies showing that 89% of patients face barriers. The most common obstacles include forgetfulness (77%), depression (57%), and behaviors driven by side effects (49%). Medication side effects are reported by approximately 72% of patients, leading to discontinuation in 78% of those cases, a problem often exacerbated by polypharmacy.

• Persistent Functional Impairment and Safety Concerns: Even with treatment, patients often exhibit significant functional deficits that impact safety and daily activities. For example, studies on driving performance show that treated NT1 patients still have impaired abilities, with one study noting a significant 1.90 cm increase in the standard deviation of lateral position (SDLP) compared to controls. In the same study, several treated patients had to prematurely stop a driving test due to emergent somnolence.

• Unaddressed Comorbidities and Psychosocial Burden: The management of NT1 often neglects the significant psychosocial and academic problems that frequently accompany the disorder. Furthermore, individuals with narcolepsy have an increased prevalence of cardiovascular and cardiometabolic comorbidities. This necessitates early and proactive monitoring for cardiovascular risks, especially since the disease typically manifests in adolescence or young adulthood.

Orzeyful: Restoring Orexin Signaling and Its Clinical Impact

Recent analyses continue to affirm the role of established therapies while highlighting evidence gaps. A 2026 systematic review and meta-analysis, which included five studies with 997 adult patients, confirmed the short-term efficacy of modafinil versus placebo for narcolepsy. The results demonstrated that modafinil significantly improved Maintenance of Wakefulness Test (MWT) scores (MD = 3.56) and reduced Epworth Sleepiness Scale (ESS) scores (MD = -3.34). However, the analysis was based on legacy RCTs from the 1990s and early 2000s, underscoring a lack of modern, long-duration trials to establish long-term efficacy and safety. Complementing this, a 12-year retrospective study from Saudi Arabia involving 43 patients found that treatment, predominantly with modafinil (69%), effectively reduced excessive daytime sleepiness, with mean ESS scores decreasing from 18.4 to 9.2 (p < 0.001). This study also noted that patients with narcolepsy type 1 (NT1) had significantly higher baseline ESS scores and shorter mean sleep latencies compared to those with type 2.

In the search for alternative treatment modalities, the upcoming TARGET-2 trial is exploring a non-pharmacological approach. This randomized, double-blind, sham-controlled study, registered in China, is designed to evaluate the safety and efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) in 153 patients with NT1. The trial will feature three arms: bilateral taVNS, unilateral taVNS, and sham stimulation, with treatment administered for 30 minutes twice daily over 12 weeks. The primary efficacy endpoint is the change in the ESS score from baseline to the 12-week follow-up. Secondary outcomes will provide a comprehensive assessment by measuring changes in the narcolepsy severity scale, Pittsburgh Sleep Quality Index, and scales for fatigue, anxiety, and depression. The trial is motivated by the limited efficacy and adverse effect profiles of some current pharmacological options.

Alongside investigations into novel interventions, clinical guidance is evolving for new formulations of existing treatments. A 2026 modified Delphi panel of seven advanced practice providers issued consensus recommendations for once-nightly sodium oxybate (ON-SXB), an extended-release formulation approved for cataplexy or excessive daytime sleepiness in narcolepsy. As ON-SXB has only been commercially available since 2023, the recommendations address practical implementation, including managing patient expectations, dosing and titration, and transitioning from twice-nightly oxybate formulations. Notably, for patients on polypharmacy, the panel recommended that stimulants should be the first medication to adjust after determining a patient's readiness to modify their concomitant narcolepsy treatments. The guidance also stressed the importance of framing discussions about sodium intake within the context of a patient’s overall cardiovascular risk profile and the benefits of consolidated sleep.

Reshaping the Narcolepsy Type 1 Treatment Landscape with Orzeyful

The therapeutic landscape for narcolepsy type 1 has recently been shaped by the emergence of novel mechanisms, particularly oral orexin receptor 2-selective agonists. Phase 2 trial data for oveporexton (TAK-861) showed significant efficacy in treating core symptoms. At week 8, oveporexton demonstrated dose-dependent, statistically significant improvements in wakefulness compared to placebo, with mean changes from baseline in average sleep latency on the Maintenance of Wakefulness Test (MWT) ranging from 12.5 to 25.4 minutes versus -1.2 minutes for placebo (adjusted P≤0.001 for all comparisons). Correspondingly, Epworth Sleepiness Scale (ESS) scores improved by -8.9 to -13.8 points versus -2.5 for placebo (adjusted P≤0.004). Certain doses also significantly reduced the weekly incidence of cataplexy. The most common adverse events were insomnia, urinary urgency, and urinary frequency, with no hepatotoxic effects observed.

Concurrently, comparative analyses and reformulations of existing therapies have provided clearer guidance for treatment selection. A 2022 network meta-analysis of 19 randomized controlled trials concluded that while solriamfetol achieved the highest efficacy ranking for improving excessive daytime sleepiness (EDS), the efficacy-safety profiles of pitolisant, sodium oxybate, and modafinil were more balanced. This suggests treatment choice should be individualized. In this context, the development of lower-sodium oxybate (LXB) represents a significant evolution, offering the same active moiety as traditional sodium oxybate but with a 92% reduction in sodium content. Phase 3 trials confirmed LXB's efficacy and a safety profile consistent with its predecessor, with headache, nausea, and dizziness being the most common short-duration adverse events. LXB is approved for EDS and cataplexy in patients aged 7 and older, with the added potential long-term benefits of reduced cardiovascular risk and weight loss.

Real-world prescribing trends reflect this evolving landscape. Data from England (2019-2022) revealed a 49.1% increase in the issuance of high-cost narcolepsy drugs, with sodium oxybate and pitolisant dominating the market share. In Sweden, stimulants remain the most commonly prescribed treatment for both incident (57.0%) and prevalent patients, and frequent treatment switching from modafinil to stimulants is common. Despite the availability of newer agents, traditional therapies like modafinil continue to demonstrate effectiveness, with a Saudi Arabian study showing significant ESS score reductions from 18.4 to 9.2 (p < 0.001) in a cohort treated predominantly with modafinil. These patterns highlight a dynamic market where newer, targeted therapies are gaining traction alongside established treatments, although significant diagnostic delays persist.